Navigation Links
Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
Date:1/8/2008

MINNEAPOLIS, Jan. 8 /PRNewswire/ -- Fairview Specialty Pharmacy today announced that it has been selected by BioMarin Pharmaceutical, Inc. to be a participating pharmacy in the specialty pharmacy limited distribution network for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU).

Kuvan was approved by the U.S. Food and Drug Administration (FDA) on December 13 and is now available through Fairview Specialty Pharmacy for patients who are prescribed this treatment by their physicians.

Kari Amundson, Fairview Specialty Pharmacy Director, commented, "We are pleased to be selected by BioMarin to launch this new drug therapy. This distributor agreement is critical to our growth strategy and our ability to provide comprehensive care to patients across the Midwest and at the University of Minnesota Medical Center, Fairview."

"Kuvan is an important breakthrough in the treatment of PKU," said Chester Whitley, Ph.D, M.D., Director of Advanced Therapy Services at the University of Minnesota Medical Center, Fairview. "We are fortunate to have Fairview Specialty Pharmacy as one of the limited specialty distribution providers for this drug."

"We are extremely pleased to be working with specialty pharmacies like Fairview to make this promising new treatment option available to PKU patients and their families," said Stephen Aselage, Senior Vice President of Global Commercial Operations for BioMarin Pharmaceutical.

About Kuvan

Kuvan(TM) (sapropterin dihydrochloride) Tablets is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of market exclusivity in the United States. In November 2007, Merck Serono submitted a Marketing Authorization Application (MAA) to the EMEA for sapropterin dihydrochloride as an oral treatment for patients suffering from HPA due to PKU or BH4 deficiency. If approved in the EU, it will receive 10 years of market exclusivity for this indication.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. To learn more about PKU, please visit http://www.PKU.com.

About Fairview Specialty Pharmacy

Fairview Specialty Pharmacy provides personal medication management services to patients who take high-cost or self-injected drugs for chronic conditions. Fairview Specialty Pharmacy ensures that patients receive their medications safely and on time via services including medication management and monitoring, free shipping anywhere in the US, and monthly refill reminder phone calls. All calls are answered by "live" pharmacists, and Patient Financial Advocates(SM) are available to help patients with insurance and billing issues. To learn more, visit http://www.FairviewSpecialtyPharmacy.org.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com.


'/>"/>
SOURCE Fairview Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
2. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
3. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
4. Albemarle Raises Prices of Specialty Aluminas
5. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
6. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
7. Survey shows gender differences are factor when surgeons in training choose a subspecialty
8. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. Mylan Announces Management of Specialty Business, Dey L.P.
11. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
Breaking Medicine Technology: